COLLEGEVILLE, Pa. (AP) - Wyeth and Progenics Pharmaceuticals Inc. said Thursday that early results from a late-stage trial of their drug Relistor did not meet its goal in restoring gastrointestinal function following surgery to the intestine. The study, in a condition known as post-operative...
[read full story]